Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: ACH-0141625 (Sovaprevir)
DRUG: ACH-0141625 (Sovaprevir)
DRUG: ACH-0141625 (Sovaprevir)
DRUG: Placebo
DRUG: Pegylated Interferon alpha-2a
DRUG: Ribavirin

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]